Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Receives $10M Equity Investment from Sanofi-Aventis

Premium

Regulus Therapeutics said this week that it has received a $10 million equity investment from Sanofi-Aventis as part of the companies' recently announced microRNA therapeutics alliance.

In June, Regulus announced that it had inked a deal giving Sanofi-Aventis the worldwide, exclusive rights to use its technology and know-how to discover, develop, and commercialize miRNA drugs, including a fibrosis treatment targeting miR-21 (GSN 6/34/2010).

“With the addition of $10 million from the Sanofi-Aventis equity investment, Regulus has to date raised $40 million from equity financings and over $58 million from strategic pharmaceutical alliances,” Garry Menzel, executive vice president of corporate development and finance at Regulus, said in a statement.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.